ReviewJournal of Parkinson's disease2018
Therapies to Slow, Stop, or Reverse Parkinson's Disease.
Review in Journal of Parkinson's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Longitudinal qualitative assessment of meaningful symptoms and relevance of WATCH-PD digital measures for people with early Parkinson's.Journal of neurology · 2025Article
- Quantitative and causal analysis for inflammatory genes and the risk of Parkinson's disease.Frontiers in immunology · 2023Article
- The Effects of a Dance and Music-Based Intervention on Parkinson's Patients' Well-Being: An Interview Study.International journal of environmental research and public health · 2022Article
- T cells, α-synuclein and Parkinson disease.Handbook of clinical neurology · 2022Review
- Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification.Frontiers in immunology · 2022Review
- Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field.Journal of neurology · 2021Review
- Parkinson's Disease: We Care!Journal of Parkinson's disease · 2020Article
- What People with Parkinson's Disease Want.Journal of Parkinson's disease · 2020Review
- Multi-parameter Behavioral Phenotyping of the MPP+ Model of Parkinson's Disease in Zebrafish.Frontiers in behavioral neuroscience · 2020Article
- Probiotics for Parkinson's Disease.International journal of molecular sciences · 2019Review
- Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Our understanding of PD pathophysiology is vastly improved compared to the situation 20 years ago. We have identified the major genetic risks for PD, we now have far more representative animal models of the disease, and we can be inspired by the early successes of others using Antisense Oligonucleotide and vaccination approaches in other neurodegenerative diseases. We also have a broad range of repurposed drugs showing the first signals of potential efficacy in the translational pipeline which are being driven forward through the various clinical trial stages. We believe we can be optimistic that the next 20 years will be a time for major breakthroughs towards the discovery of therapies that may slow, stop, or reverse PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.